507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

Pasi A. Jänne, BC Wang, Byoung Chul Cho, Jun Zhao, Jiaqi Li, Maximilian J. Hochmair, Solange Peters, Benjamin Besse, Terufumi Kato, Yi‐Long Wu, D. Nguyen, Jianchang Lin, Jianchang Lin, Florin Vranceanu, Melanie Lin, Robert J. Fram, Tony Mok